Skip to content

Pipeline

iCoat Medical’s product portfolio addresses several health issues that are connected to ischemia reperfusion injury. The table below shows what stage each product candidate has reached in the development cycle.

Pharmaceutical products
Candidate / Project
Usage area
Research
Preclinical studies
Clinical preparation
Phase I
Phase 2
Phase 3 (1)
Expected next step
iCoat Medical’s technology platform
TUM012
Kidney transplantation
Completion of study in H1 2023
Heart transplantation
Development plan completed – Q1 2023
Cardiopulmonary bypass – open heart surgery and ECMO
Development plan completed – Q1 2023
Lung transplantation
Cell tests initiated – H2 2022
TUM020
Stroke
Ongoing
research
Myocardial infarction
Cardiopulmonary bypass – open heart surgery, ECMO
Completed
Ongoing
Planning

1) Depending on Orphan Drug Designation and outcome of phase I + phase II studies, a traditional phase III study may not be needed